Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Satoshi Oizimi"'
Autor:
Hisashi Tanaka, Yukihiro Hasegawa, Yuka Fujita, Atsushi Nakamura, Eiki Kikuchi, Yasutaka Kawai, Toshiyuki Harada, Naomi Watanabe, Hiroshi Yokouchi, Kazuhiro Usui, Ryota Saito, Hiroshi Watanabe, Tomomi Masuda, Tatsuro Fukuhara, Keita Kudo, Ryoichi Honda, Satoshi Oizimi, Makoto Maemondo, Akira Inoue, Naoto Morikawa
Publikováno v:
Thoracic Cancer, Vol 12, Iss 14, Pp 2113-2121 (2021)
Abstract Background A cisplatin plus irinotecan (CPT‐11) regimen is used for patients with extensive disease small cell lung cancer (ED‐SCLC). Amrubicin (AMR) is primarily used for relapsed SCLC. The HOT1401/NJLCG1401 trial, an open‐label rando
Externí odkaz:
https://doaj.org/article/c0e9bc75e14647f5afcebfe007cf88f5
Autor:
Keita Kudo, Tomomi Masuda, Toshiyuki Harada, Kazuhiro Usui, Eiki Kikuchi, Yukihiro Hasegawa, Akira Inoue, Satoshi Oizimi, Atsushi Nakamura, Makoto Maemondo, Tatsuro Fukuhara, Yuka Fujita, Ryoichi Honda, Hiroshi Yokouchi, Hiroshi Watanabe, Naomi Watanabe, Hisashi Tanaka, Ryota Saito, Naoto Morikawa, Yasutaka Kawai
Publikováno v:
Thoracic Cancer, Vol 12, Iss 14, Pp 2113-2121 (2021)
Thoracic Cancer
Thoracic Cancer
Background A cisplatin plus irinotecan (CPT‐11) regimen is used for patients with extensive disease small cell lung cancer (ED‐SCLC). Amrubicin (AMR) is primarily used for relapsed SCLC. The HOT1401/NJLCG1401 trial, an open‐label randomized pha